Maravai LifeSciences Holdings Inc(MRVI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 5:11 AM ET (Korea 10/26 18:11)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.53 | Insider Own | 25.31% | Shs Outstand | 148.9M | Perf Week | 7.81% |
| Market Cap | 1.90B | Forward P/E | - | EPS next Y | 7.16% | Insider Trans | -0.08% | Shs Float | 111.3M | Perf Month | -4.31% |
| Enterprise Value | 2.16B | PEG | - | EPS next Q | -0.06 | Inst Own | 81.91% | Short Float | 12.42% | Perf Quarter | 9.42% |
| Income | -0.08B | P/S | 9.1 | EPS this Y | 62.67% | Inst Trans | 7.85% | Short Ratio | 4.39 | Perf Half Y | 106.2% |
| Sales | 0.21B | P/B | 5.33 | EPS next 5Y | 37.17% | ROA | -10.31% | Short Interest | 13.83M | Perf YTD | 125.23% |
| Book/sh | 1.37 | P/C | 26.93 | EPS past 3/5Y | - | ROE | -32.9% | 52W High | -22.29% ($9.42) | Perf Year | 110.34% |
| Cash/sh | 0.27 | P/FCF | - | Sales past 3/5Y | -40.53% -8.15% | ROIC | -20.35% | 52W Low | 187.62% ($2.55) | Perf 3Y | 9.91% |
| Dividend Est. | - | EV/EBITDA | 75.48 | EPS Y/Y TTM | 61.09% | Gross Margin | 34.32% | Volatility(W/M) | 7.56% 6.62% | Perf 5Y | -82.57% |
| Dividend TTM | - | EV/Sales | 10.34 | Sales Y/Y TTM | -3.28% | Oper. Margin | -13.4% | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.98 | EPS Q/Q | 69.44% | Profit Margin | -37.07% | RSI (14) | 51.08 | Recom | 1.89 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.05 | Sales Q/Q | 8.53% | SMA20 | -0.37% ($7.35) | Beta | 0.63 | Target Price | $8.5 |
| Payout | - | Debt/Eq | 0.86 | Earnings | 2026/11/4 | SMA50 | -0.24% ($7.34) | Rel Volume | 0.46 | Prev Close | $7.07 |
| Employees | 435 | LT Debt/Eq | 0.86 | EPS/Sales Surpr. | 54.02% 5.69% | SMA200 | 42.67% ($5.13) | Avg Volume(3M) | 3.15M | Price | $7.32 |
| IPO | 2020/11/20 | Option/Short | Yes/Yes | Trades | 7774 | Volume | 1,447,692 | Change | 3.54% |
🧬 Maravai LifeSciences (MRVI) is a U.S. life-sciences tools company that supplies nucleic acid synthesis and biosafety testing materials used in the development and manufacturing of mRNA vaccines and therapeutics. The company provides proprietary reagents, including its CleanCap mRNA capping technology, as well as raw materials for production, to pharmaceutical and biotech customers, serving as a key infrastructure provider in the drug development and manufacturing process.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
Next earnings report: November 4
9 days to go.
MRVI has weak earning power
Of every $100 in sales, $13.40 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +62.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $910. Peers typically go for $1,091.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -82.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 81.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #100 of 595 in the industry
Based on market cap of $2B.
BRVE#99 Braveheart Bio Inc $2B PER - MRVI#100 Maravai LifeSciences Holdings Inc $2B PER - 
SEPN#101 Septerna Inc $2B PER - 
SRPT#102 Sarepta Therapeutics Inc $2B PER - 
XNCR#103 Xencor Inc $2B PER - 
FAQ
What kind of company is MRVI?
MRVI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MRVI?
The market cap of MRVI is approximately $1.9B, ranking 2,090 within its sector.
What is the 52-week high and low for MRVI?
MRVI has recorded a 52-week high of $9.42 and a low of $2.55.
